Drug Trial Radar · NCT00111020
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Aug 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,567
Actual
Start
Jun 2005
Primary completion
Jun 2007
Study completion Oct 2008
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- May 17, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib, BAY43-9006, which is being studied in clinical trials for kidney cancer and other kinds of cancer. This treatment protocol is not a clinical trial in which sorafenib is compared to another equal treatment. All patients in this protocol will be treated with sorafenib. In addition, data from the patients who participate in this protocol will provide additional information about the drug.
Conditions
- Carcinoma, Renal Cell
Interventions
Sorafenib (Nexavar, BAY43-9006)Drug
Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety parametersTime frame: From signing consent to 30 days after last dose of study drug
Locations
320 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Bessemer, Alabama
Site not named
Cullman, Alabama
Site not named
Mobile, Alabama
Site not named
Anchorage, Alaska
Site not named
Glendale, Arizona
Site not named
Scottsdale, Arizona
Site not named
Tucson, Arizona
Site not named
Conway, Arkansas
Site not named
Hot Springs, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Pine Bluff, Arkansas
Site not named
Springdale, Arkansas
Site not named
Bakersfield, California
Site not named
Beverly, California
Site not named
Concord, California
Site not named
Duarte, California
Site not named
Fountain Valley, California
Site not named
Glendale, California
Site not named
Highland, California
Site not named
La Jolla, California
Site not named
La Jolla, California
Site not named
Loma Linda, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Newport Beach, California
Site not named
Orange, California
Site not named
Rancho Mirage, California
Site not named
Sacramento, California
Site not named
Salinas, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Stanford, California
Site not named
Sunnyvale, California
Site not named
Vallejo, California
Site not named
Aurora, Colorado
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Showing 40 of 320 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.